AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Aug 1, 2017
35334_dirs_2017-08-01_9edcc7b2-7b83-4b4f-a66c-c7c09863956a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-07-31
Reporting Person: Springate Wayne S. (Sr. VP of Operations)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-31 | Options to buy Common Stock | $0.42 | A | 6236 | Acquired | 2027-07-31 | Common Stock (6236) | Direct |
Footnotes
F1: This option is being issued in exchange for a voluntary 20% deduction in salary.